| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Tuesday’s Close |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | $105.71 | $113.53B | N/A |
Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice
http://www.zacks.com/stock/news/430445/are-you-looking-for-a-high-growth-dividend-stock-eli-lilly-lly-could-be-a-great-choice?cid=CS-ZC-FT-430445
Jun 17, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
0
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
http://www.zacks.com/stock/news/429560/pharma-stock-roundup-mrk-buys-small-cancer-biotech-rhhby-mrk-drugs-get-fda-nod?cid=CS-ZC-FT-429560
Jun 14, 2019 - Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
0
Boost Your Portfolio's Health With These 3 Big Drug Stocks
http://www.zacks.com/stock/news/428332/boost-your-portfolios-health-with-these-3-big-drug-stocks?cid=CS-ZC-FT-428332
Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
0
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
http://www.zacks.com/stock/news/427738/lilly-announces-tradjenta-cardiovascular-outcome-study-data?cid=CS-ZC-FT-427738
Jun 11, 2019 - Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
0
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
http://www.zacks.com/stock/news/427724/merck-mrk-to-buy-private-biotech-tilos-for-up-to-%24773m?cid=CS-ZC-FT-427724
Jun 11, 2019 - Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
0
Top Analyst Reports for Oracle, Eli Lilly & Mondelez
http://www.zacks.com/research-daily/427196/top-analyst-reports-for-oracle-eli-lilly-mondelez?cid=CS-ZC-FT-427196
Jun 10, 2019 - Top Analyst Reports for Oracle, Eli Lilly & Mondelez
0
Lilly (LLY) Presents Data From Diabetes Studies at ADA Meet
http://www.zacks.com/stock/news/427034/lilly-lly-presents-data-from-diabetes-studies-at-ada-meet?cid=CS-ZC-FT-427034
Jun 10, 2019 - Lilly (LLY) presents additional data from studies on investigational diabetes products ultra-rapid-acting lispro and tirzepatide and outcomes study (REWIND) on Trulicity at ADA.
0
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
http://www.zacks.com/stock/news/426292/pharma-stock-roundup-asco-update-fda-nod-for-llys-emgality-for-cluster-headache?cid=CS-ZC-FT-426292
Jun 07, 2019 - Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
0
Incyte Begins Phase III Study for Treatment of Duct Cancer
http://www.zacks.com/stock/news/425849/incyte-begins-phase-iii-study-for-treatment-of-duct-cancer?cid=CS-ZC-FT-425849
Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
0
Lilly's Emgality Gets FDA Approval for Cluster Headache
http://www.zacks.com/stock/news/425463/lillys-emgality-gets-fda-approval-for-cluster-headache?cid=CS-ZC-FT-425463
Jun 06, 2019 - Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
0